Elacestrant
123 interactions 283 cited referencesElacestrant is used to treat certain types of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults who have had disease progression following treatment with at least one other hormone therapies. Elacestrant is in a class of medications called estrogen recep… Read the full Elacestrant drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Elacestrant Fluvoxamine Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Fosnetupitant Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Fosphenytoin Cerebyx Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Idelalisib Zydelig Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Imatinib Gleevec Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Indinavir Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Elacestrant Itraconazole Sporanox Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Ketoconazole Extina Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Elacestrant Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Elacestrant Letermovir Prevymis Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Elacestrant Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Elacestrant Lopinavir Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Lorlatinib Lorbrena Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Lumacaftor Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Mavorixafor Xolremdi Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Elacestrant Mifepristone Korlym Increased CYP3A4 substrate exposure Details Elacestrant Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Elacestrant Mitotane Lysodren Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Modafinil Provigil Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Morphine Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Elacestrant Morphine Sulfate Liposome Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Elacestrant Nafcillin Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Nefazodone Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Nelfinavir Viracept Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Netupitant Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Nilotinib Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Elacestrant Phenobarbital Fidoquel Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Phenytoin Dilantin Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Posaconazole Noxafil Increased elacestrant exposure, an increased risk of elacestrant-related adverse effects and an increased posaconazole exposure Details Elacestrant Primidone Mysoline Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Ranolazine Aspruzyo Increased ranolazine exposure and an increased CYP3A4 substrate exposure Details Elacestrant Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Elacestrant Repotrectinib Augtyro Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Elacestrant Ribociclib Kisqali Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Rifabutin Mycobutin Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Rifampin Rifadin Reduced elacestrant exposure and reduced efficacy of elacestrant DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist